GlassScriptPhysician profile
Cynthia L Coe
NPI 1528758463
$7,649.14
in general payments reported to CMS, 2019-2025
23 companies · $3,405 in 2025
The $3,405 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,305 · 2024: $2,939 · 2025: $3,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,594 · Education: $55.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,593.78 |
| Education | $55.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,199.74 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,099.00 | 2023-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $780.65 | 2023-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $737.37 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $617.42 | 2023-2025 | Lybalvi, Aristada |
| E.R. Squibb & Sons, L.L.C. | $576.40 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $551.13 | 2023-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Ironshore Pharmaceuticals INC. | $302.94 | 2023-2024 | Jornay Pm |
| Corium, LLC | $302.71 | 2023-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $249.98 | 2023-2025 | Ingrezza |
| Collegium Pharmaceutical, INC. | $238.74 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $192.26 | 2023-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $148.40 | 2023-2025 | Rexulti |
| Bausch Health US, LLC | $117.76 | 2024-2025 | Aplenzin, Wellbutrin |
| Tris Pharma INC | $95.72 | 2023-2025 | Dyanavel Xr, Onyda Xr |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $79.86 | 2024 | Loreev Xr |
| Axsome Therapeutics, INC. | $78.44 | 2024-2025 | Auvelity |
| Noven Therapeutics, LLC | $74.37 | 2023-2025 | Xelstrym, Secuado |
| Idorsia Pharmaceuticals US INC | $66.02 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $53.31 | 2024 | Trintellix |
| Neos Therapeutics, LP | $37.46 | 2024-2025 | Adzenys Xr-Odt |
| Acadia Pharmaceuticals INC | $24.74 | 2025 | Daybue |
| Teva Pharmaceuticals USA, INC. | $24.72 | 2025 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Coe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.